Publicacións en colaboración con investigadores/as de Universitat Autònoma de Barcelona (20)

2024

  1. Multidrug-resistant bacterial infections after liver transplantation: Prevalence, impact, and risk factors

    Journal of Hepatology, Vol. 80, Núm. 6, pp. 904-912

  2. Role of SARS-CoV-2-specific memory B cells promoting immune protection after booster vaccination in solid organ transplantation

    Frontiers in Immunology, Vol. 15

2022

  1. Reconciling short-term clinical and immunological outcomes of SARS-CoV-2 vaccination in solid organ transplant recipients

    American Journal of Transplantation

  2. Safety of Drugs Used during the First Wave of COVID-19: A Hospital-Registry-Based Study

    Diagnostics, Vol. 12, Núm. 7

2021

  1. Low seroprevalence of SARS-CoV-2 antibodies in a liver transplant cohort

    Transplant International, Vol. 34, Núm. 10, pp. 1908-1913

2020

  1. Recipient Age for Liver Transplantation: Should It Be Limited? A Propensity Score Matching Analysis of a Large European Series

    Transplantation Proceedings, Vol. 52, Núm. 5, pp. 1442-1449

2018

  1. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

    American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522

2017

  1. Sofosbuvir and daclatasvir in mono-and HIV-coinfected patients with recurrent hepatitis C After liver transplant

    Annals of Hepatology, Vol. 16, Núm. 1, pp. 86-93

2016

  1. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

2015

  1. Analysis of adult 20-year survivors after liver transplantation

    Hepatology International, Vol. 9, Núm. 3, pp. 461-470

  2. Doubtful role of IL28B polymorphism in occult Hepatitis B infection

    Intervirology, Vol. 58, Núm. 3, pp. 160-165

2014

  1. Early predictors of antiviral treatment response in liver transplant recipients with recurrent hepatitis C genotype 1

    Journal of Viral Hepatitis, Vol. 21, Núm. 10, pp. e118-e128

  2. Outcome of early vs. Deferred antiviral treatment for recurrent hepatitis C in liver transplant recipients

    Annals of Hepatology, Vol. 13, Núm. 2, pp. 219-230

2012

  1. IL28B genetic variation and hepatitis C virus-specific CD4+ T-cell responses in anti-HCV-positive blood donors

    Journal of Viral Hepatitis, Vol. 19, Núm. 12, pp. 867-871

  2. Reversal of nonstructural protein 3-specific CD4 + T cell dysfunction in patients with persistent hepatitis C virus infection

    Journal of Viral Hepatitis, Vol. 19, Núm. 4, pp. 283-294

  3. Transjugular intrahepatic portosystemic shunt for the treatment of sinusoidal obstruction syndrome in a liver transplant recipient and review of the literature

    Liver Transplantation, Vol. 18, Núm. 2, pp. 201-205

2011

  1. Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIG and Nucleoside Analogues?

    Annals of Hepatology, Vol. 10, Núm. 2, pp. 180-187

  2. Hyperkalemic distal renal tubular acidosis caused by immunosuppressant treatment with tacrolimus in a liver transplant patient: Case report

    Transplantation Proceedings

  3. Pretransplantation liver function impacts on the outcome of allogeneic hematopoietic stem cell transplantation: A study of 455 patients

    Biology of Blood and Marrow Transplantation, Vol. 17, Núm. 11, pp. 1653-1661

2006

  1. Addisonian crises induced by rifampicin [1]

    Archivos de Bronconeumologia